Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1944436 | 0.82 | CACNA2D1 (0.42) | TDP1ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL732270 | 0.82 | TDP1 (0.36) | TDP1ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL18880151 | 0.81 | — | — | |
| SCHEMBL553900 | 0.76 | — | — | |
| SCHEMBL8401516 | 0.76 | — | — | |
| SCHEMBL17183778 | 0.76 | SLC7A5 (0.41) | TDP1ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL8402309 | 0.76 | — | — | |
| SCHEMBL3804215 | 0.76 | — | — | |
| SCHEMBL15295735 | 0.75 | — | — | |
| SCHEMBL13235783 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818718-B2 | IMPROVED SEPARATION OF PROTEINS, ENZYMES, PEPTIDES, OLIGONUCLEOTIDES, POLYNUCLEOTIDES, AND CARBOHYDRATES | THE UNIVERSITY OF MELBOURNE (AU) | 2004-11-16 | — | — | US | disclosed |
| US-20010020079-A1 | Electrophoresis gels and cross-linking agents for their preparation | THE UNIVERSITY OF MELBOURNE | 2001-09-06 | — | — | US | disclosed |
| US-6197906-B1 | ASSYMETRIC AGENTS SUCH AS (2-METHACRYLOYLOXYETHYL)ACRYLAMIDE, (2-ACRYLOYLOXYETHYL)METHACRYLAMIDE, AND (N-METHYL-N-ACRYLOYLAMINO)ETHYL METHACRYLATE | THE UNIVERSITY OF MELBOURNE (AU) | 2001-03-06 | — | — | US | disclosed |
| EP-0920412-A4 | ELECTROPHORESIS GELS AND CROSS-LINKING AGENTS FOR THEIR PREPARATION | UNIV MELBOURNE (AU) | 2000-08-02 | — | — | EP | disclosed |
| EP-0920412-A1 | ELECTROPHORESIS GELS AND CROSS-LINKING AGENTS FOR THEIR PREPARATION | THE UNIVERSITY OF MELBOURNE (AU) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998001419-A1 | ELECTROPHORESIS GELS AND CROSS-LINKING AGENTS FOR THEIR PREPARATION | THE UNIVERSITY OF MELBOURNE (AU) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020079-A1 | Electrophoresis gels and cross-linking agents for their preparation | MACF1, ZYX, F12 | TDP1 1392/4885ALDH1A1 794/4885LMNA 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.